Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS) (AFFINITY)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With Optional Open-Label Extension in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies
Sponsor: Biogen
Terminated
The top-line results from the Part 1 did not meet the pre-specified primary endpoint nor the key secondary endpoints. The decision to discontinue study 215MS202 Part 2 was not based on safety concerns.
Other terminated trials from Biogen
Other Multiple Sclerosis trials with similar outcome
A PHASE2 clinical study on Multiple Sclerosis, this trial is terminated or withdrawn. The trial is conducted by Biogen and has accumulated 22 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
22 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
May 2022 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — May 2022 [monthly]
Terminated PHASE2
▶ Show 17 earlier versions
-
Apr 2021 — Dec 2021 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Jan 2021 — Apr 2021 [monthly]
Active Not Recruiting PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Jan 2020 — Oct 2020 [monthly]
Active Not Recruiting PHASE2
-
May 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE2
-
Jan 2019 — May 2019 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2018 — Jan 2019 [monthly]
Recruiting PHASE2
-
Jul 2018 — Sep 2018 [monthly]
Recruiting PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE2
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE2
-
Mar 2018 — May 2018 [monthly]
Recruiting PHASE2
-
Feb 2018 — Mar 2018 [monthly]
Recruiting PHASE2
-
Jan 2018 — Feb 2018 [monthly]
Recruiting PHASE2
-
Dec 2017 — Jan 2018 [monthly]
Recruiting PHASE2
-
Nov 2017 — Dec 2017 [monthly]
Recruiting PHASE2
-
Oct 2017 — Nov 2017 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Aug 2017 — Oct 2017 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Biogen
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aarau, Switzerland , Amiens, France , Atlanta, United States , Baltimore, United States , Barakaldo, Spain , Barcelona, Spain , Basel, Switzerland , Berkeley, United States , Berlin, Germany , Bern, Switzerland and 133 more locations